GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » MedAssets Inc (NAS:MDAS) » Definitions » PE Ratio (TTM)

MedAssets (MedAssets) PE Ratio (TTM) : At Loss (As of Apr. 26, 2024)


View and export this data going back to . Start your Free Trial

What is MedAssets PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-26), MedAssets's share price is $31.35. MedAssets's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2015 was $-0.59. Therefore, MedAssets's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for MedAssets's PE Ratio (TTM) or its related term are showing as below:

MDAS' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: At Loss   Max: At Loss
Current: At Loss



MDAS's PE Ratio (TTM) is not ranked
in the Healthcare Providers & Services industry.
Industry Median: 25.71 vs MDAS: At Loss

MedAssets's Earnings per Share (Diluted) for the three months ended in Sep. 2015 was $-0.04. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2015 was $-0.59.

As of today (2024-04-26), MedAssets's share price is $31.35. MedAssets's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2015 was $-0.59. Therefore, MedAssets's PE Ratio without NRI for today is At Loss.

MedAssets's EPS without NRI for the three months ended in Sep. 2015 was $-0.04. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2015 was $-0.59.

MedAssets's EPS (Basic) for the three months ended in Sep. 2015 was $-0.04. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2015 was $-0.58.


MedAssets PE Ratio (TTM) Historical Data

The historical data trend for MedAssets's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedAssets PE Ratio (TTM) Chart

MedAssets Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss 44.56 At Loss

MedAssets Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.72 N/A N/A N/A N/A

Competitive Comparison of MedAssets's PE Ratio (TTM)

For the Health Information Services subindustry, MedAssets's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedAssets's PE Ratio (TTM) Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, MedAssets's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where MedAssets's PE Ratio (TTM) falls into.



MedAssets PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

MedAssets's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=31.35/-0.593
=At Loss

MedAssets's Share Price of today is $31.35.
MedAssets's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.59.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


MedAssets  (NAS:MDAS) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


MedAssets PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of MedAssets's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


MedAssets (MedAssets) Business Description

Traded in Other Exchanges
N/A
Address
MedAssets Inc was incorporated in 1999. It is a financial and performance improvement company providing technology-enabled products and services that, together, help mitigate the increasing financial challenges faced by hospitals, health systems, and other non-acute healthcare providers. Its solutions are designed to reduce the total cost of care delivery, enhance operational efficiency, align clinical delivery of physicians and staff to advance care coordination, and improve revenue performance mainly for hospitals and health systems. The Company's solutions integrate with its clients' existing operations and enterprise software systems, and require minimal upfront costs or capital expenditures for its clients. Its technology-enabled solutions are delivered through company-hosted software, sometimes referred to as software as a service or Web-based applications, supported by implementation, process improvement consulting and outsourced services, as well as enterprise-wide sales and client management support. The Company manages its business through two business segments, Spend and Clinical Resource Management (CM) and Revenue Cycle Management (RCM). Within the SCM segment it provides a comprehensive suite of cost management services, supply chain analytics and data capabilities that help its clients reduce their total cost of care delivery, enhance their operational efficiency and align their clinicians' delivery of care with advance care coordination. Its solutions lower operating costs through compliance to its strategic sourcing of supplies and purchased services at discounted prices, supply chain outsourcing and procurement services capabilities. It also help to improve care processes and reduce care variations through the use of its clinical and process improvement consulting services, workforce optimization solutions and business analytics and intelligence tools. The Company's RCM segment is a provider of revenue cycle management solutions to healthcare providers, mainly hospitals and health systems. It provides SaaS or Web-based software and technology-enabled services designed to improve revenue performance for healthcare organizations through patient access and financial responsibility, clinical documentation, charge capture and revenue integrity, pricing analysis, claims processing and denials management, payor contract management, extended business office revenue recovery, accounts receivable services and outsourcing. As of December 31, 2013, the Company's client base included more than 4,400 acute care hospitals and approximately 122,000 ancillary or non-acute provider locations. The Company competes with Allscripts Corporation, Epic Systems Corporation, McKesson Corporation, Siemens AG; Accenture Ltd., Accretive Health, Inc., Deloitte & Touche LLP, Ernst & Young LLP, Craneware Inc., Emdeon Inc. and among others. The Company is subject to federal and state laws and regulations designed to protect patients, government
Executives
Anthony Jr Colaluca officer: Chief Financial Officer MULTIPLAN CORPORATION, 115 FIFTH AVENUE, NEW YORK NY 10003
Bharat Sundaram officer: President, SCM Segment 100 NORTH POINT CENTER EAST, SUITE 200, ALPHARETTA GA 30022
C A Piccolo director 199 BENSON RD, MIDDLEBURY CT 06749
Carol J Zierhoffer director 100 NORTH POINT CENTER EAST, SUITE 200, ALPHARETTA GA 30022
Kevin M Twomey director 1650 PRUDENTIAL DR, STE 400, JACKSONVILLE FL 32207
Bruce F Wesson director 1827 PACIFIC ST BROOKLYN NY 11233
R Halsey Wise director, officer: Chairman and CEO 135 PONTE VEDRA BLVD, PONTE VEDRA BEACH FL 32082
Samuel K Skinner director 233 NORTH MICHIGAN AVENUE, 22ND FLOOR, CHICAGO IL 60601
Loucks Vernon R Jr director 1101 SKOKIE BLVD., SUITE 240, NORTHBROOK IL 60062
Laurence Neil Hunn officer: President, Revenue Cycle Tech 100 NORTH POINT CENTER EAST, SUITE 200, ALPHARETTA GA 30022
Patrick T Ryan director, officer: President, SCM Segment 401 EDGEWATER PLACE, SUITE 500, WAKEFIELD MA 01880
Claudius Llc 10 percent owner C/O GALEN ASSOCIATES 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020
Galen Partners Iii L P 10 percent owner 610 FIFTH AVE 5TH FL NEW YORK NY 10020
Galen Partners International Iii L P 10 percent owner 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020
Galen Employee Fund Iii Lp 10 percent owner 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020

MedAssets (MedAssets) Headlines

From GuruFocus

MEDASSETS, INC. (MDAS) CFO Laurence Neil Hunn sells 3,100 Shares

By GuruFocus Research GuruFocus Editor 04-16-2010

MEDASSETS, INC. (MDAS) CFO Laurence Neil Hunn sells 3,100 Shares

By GuruFocus Research GuruFocus Editor 03-01-2010

MEDASSETS, INC. (MDAS) COO Rand A Ballard sells 4,300 Shares

By GuruFocus Research GuruFocus Editor 07-08-2010

MEDASSETS, INC. (MDAS) CFO Laurence Neil Hunn sells 3,100 Shares

By GuruFocus Research GuruFocus Editor 07-08-2010

MEDASSETS, INC. (MDAS) Chairman, President and CEO John A Bardis sells 54,000 Shares

By GuruFocus Research GuruFocus Editor 03-01-2010

MEDASSETS, INC. (MDAS) COO Rand A Ballard sells 15,000 Shares

By GuruFocus Research GuruFocus Editor 01-05-2011

MEDASSETS, INC. (MDAS) COO Rand A Ballard sells 15,000 Shares

By GuruFocus Research GuruFocus Editor 02-09-2011

MEDASSETS, INC. (MDAS) Chairman, President and CEO John A Bardis sells 40,000 Shares

By GuruFocus Research GuruFocus Editor 06-03-2010

MEDASSETS, INC. (MDAS) COO Rand A Ballard sells 15,000 Shares

By GuruFocus Research GuruFocus Editor 12-08-2010

MEDASSETS, INC. (MDAS) Chairman, President and CEO John A Bardis sells 26,776 Shares

By GuruFocus Research GuruFocus Editor 03-01-2010